134 related articles for article (PubMed ID: 22594924)
1. Proliferative retinopathy in Duchenne muscular dystrophy and its response to bevacizumab.
Fagan XJ; Levy J; Al-Qureshi S; Harper CA
Clin Exp Ophthalmol; 2012 Dec; 40(9):906-7. PubMed ID: 22594924
[No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy.
Ernst BJ; García-Aguirre G; Oliver SC; Olson JL; Mandava N; Quiroz-Mercado H
Acta Ophthalmol; 2012 Nov; 90(7):e573-4. PubMed ID: 22405048
[No Abstract] [Full Text] [Related]
3. Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy.
Yamaji H; Shiraga F; Shiragami C; Nomoto H; Fujita T; Fukuda K
Arch Ophthalmol; 2011 Jan; 129(1):106-7. PubMed ID: 21220639
[No Abstract] [Full Text] [Related]
4. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.
Roller AB; Folk JC; Patel NM; Boldt HC; Russell SR; Abramoff MD; Mahajan VB
Retina; 2011 Oct; 31(9):1848-55. PubMed ID: 21610563
[TBL] [Abstract][Full Text] [Related]
6. Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.
Ozkaya A; Alkin Z; Karakucuk Y; Yazici AT; Demirok A
Middle East Afr J Ophthalmol; 2013; 20(4):360-2. PubMed ID: 24339691
[TBL] [Abstract][Full Text] [Related]
7. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
Spandau U
Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
[No Abstract] [Full Text] [Related]
8. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.
Park SW; Jung HH; Heo H
Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062
[No Abstract] [Full Text] [Related]
9. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.
Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2006 Oct; 84(5):707-8. PubMed ID: 16965507
[No Abstract] [Full Text] [Related]
10. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy.
Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
J AAPOS; 2014 Apr; 18(2):120-3. PubMed ID: 24698606
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
12. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.
Narayanan R; Chhablani J; Sinha M; Dave V; Tyagi M; Pappuru RR; Kuppermann BD
Retina; 2012; 32(10):2001-5. PubMed ID: 22990322
[TBL] [Abstract][Full Text] [Related]
14. RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
Manabe A; Shimada H; Hattori T; Nakashizuka H; Yuzawa M
Retina; 2015 Sep; 35(9):1800-7. PubMed ID: 25932549
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
[TBL] [Abstract][Full Text] [Related]
16. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).
Isaacs TW; Barry C
Clin Exp Ophthalmol; 2006 Nov; 34(8):802-3. PubMed ID: 17073910
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
Siqueira RC; Costa RA; Scott IU; Cintra LP; Jorge R
Acta Ophthalmol Scand; 2006 Dec; 84(6):834-5. PubMed ID: 17083555
[No Abstract] [Full Text] [Related]
18. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
Jorge R; Costa RA; Calucci D; Cintra LP; Scott IU
Retina; 2006; 26(9):1006-13. PubMed ID: 17151487
[TBL] [Abstract][Full Text] [Related]
19. Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization.
Stergiou PK; Symeonidis C; Dimitrakos SA
Acta Ophthalmol; 2011 May; 89(3):218-21. PubMed ID: 19860769
[TBL] [Abstract][Full Text] [Related]
20. Multifocal outer retinopathy in a patient with multifocal inner choroidopathy.
Chen FK; Tufail A
Clin Exp Ophthalmol; 2011; 39(7):700-3. PubMed ID: 22452687
[No Abstract] [Full Text] [Related]
[Next] [New Search]
